LGD 4665

Drug Profile

LGD 4665

Alternative Names: 2285921; GSK-2285921; GSK-5291

Latest Information Update: 02 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ligand Pharmaceuticals
  • Developer GlaxoSmithKline; Ligand Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Thrombopoietin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Idiopathic thrombocytopenic purpura

Most Recent Events

  • 02 Sep 2015 No recent reports on development identified - Phase-II for Idiopathic thrombocytopenic purpura in USA (PO)
  • 18 Dec 2008 LGD 4665 licensed to GlaxoSmithKline worldwide
  • 09 Dec 2008 Interim efficacy & adverse events data from a phase IIa trial in Immune thrombocytopenic purpura presented at the presented at the 50th Annual Meeting and Exposition of the American Society of Hematology (ASH-2008) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top